-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
-
Summary
-
Ambrx Biopharma Cayman, Inc. quarterly/annual Amortization of Intangible Assets history and growth rate from 2019 to 2022.
- Ambrx Biopharma Cayman, Inc. Amortization of Intangible Assets for the quarter ending June 30, 2023 was $200K, a 50% decline year-over-year.
- Ambrx Biopharma Cayman, Inc. annual Amortization of Intangible Assets for 2022 was $1.05M, a 34.4% decline from 2021.
- Ambrx Biopharma Cayman, Inc. annual Amortization of Intangible Assets for 2021 was $1.6M, a 10.5% increase from 2020.
- Ambrx Biopharma Cayman, Inc. annual Amortization of Intangible Assets for 2020 was $1.45M, unchanged from 2019.
Amortization of Intangible Assets, Annual (USD)
Amortization of Intangible Assets, YoY Annual Growth (%)